Jiangsu, China

Liusong Yin

USPTO Granted Patents = 6 

Average Co-Inventor Count = 5.4

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
6 patents (USPTO):

Title: Liusong Yin: Innovator in Tumor Immunotherapy

Introduction

Liusong Yin is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of tumor immunotherapy, holding a total of 6 patents. His innovative work focuses on developing bispecific antibodies that target specific immune pathways to enhance cancer treatment.

Latest Patents

One of Liusong Yin's latest patents is the "Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof." This invention relates to a bispecific antibody that includes a first antigen binding portion that specifically binds to CD47 and a second antigen binding portion that binds to PD-1. This dual-targeting approach can effectively block tumor immune escape mechanisms, demonstrating promising potential in tumor immunotherapy.

Another notable patent is the "Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof." This humanized monoclonal antibody exhibits high affinity for OX40 and stimulates T cells to secrete cytokines. By activating the OX40 signaling pathway, this antibody aims to enhance T cell responses, further contributing to effective tumor immunotherapy.

Career Highlights

Liusong Yin has worked with notable companies in the biotechnology sector, including Nanjing Genscript Biotech Co., Ltd. and Nanjing Legend Biotech Co., Ltd. His experience in these organizations has allowed him to collaborate on cutting-edge research and development projects in the field of immunotherapy.

Collaborations

Some of Liusong Yin's coworkers include Zhuo Fang and Tielin Zhou. Their collaborative efforts have contributed to the advancement of innovative therapeutic solutions in cancer treatment.

Conclusion

Liusong Yin's contributions to tumor immunotherapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for new therapeutic strategies in combating cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…